Arcus Biosciences Announces New Employment Inducement Grants

Carbonatix Pre-Player Loader

Audio By Carbonatix

HAYWARD, Calif.--(BUSINESS WIRE)--Sep 8, 2025--

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 19,300 shares of the Company’s common stock at an exercise price per share of $12.19, which was the closing price on September 8, 2025, and restricted stock units to acquire a total of 9.700 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- and/or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into registrational clinical trials including domvanalimab, an Fc-silent anti-TIGIT antibody being studied in combination with zimberelimab, an anti-PD-1 antibody, for upper gastrointestinal and non-small cell lung cancer, casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.

Inducement PR

Source: Arcus Biosciences

View source version on businesswire.com:https://www.businesswire.com/news/home/20250908291539/en/

CONTACT: Investor Inquiries:

Pia Eaves

VP of Investor Relations & Strategy

(617) 459-2006

[email protected] Inquiries:

Holli Kolkey

VP of Corporate Communications

(650) 922-1269

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH PHARMACEUTICAL CLINICAL TRIALS ONCOLOGY

SOURCE: Arcus Biosciences

Copyright Business Wire 2025.

PUB: 09/08/2025 04:35 PM/DISC: 09/08/2025 04:34 PM

http://www.businesswire.com/news/home/20250908291539/en

 

Salem News Channel Today

Sponsored Links

On Air & Up Next

  • The Main Event
    9:00PM - 10:00PM
     
    Ed discusses national current events and politics, with a few mortgage tips   >>
     
  • Firing Line Radio Show
    10:00PM - 11:00PM
     
    Rick Travis will cover the world of firearms each week in an entertaining and   >>
     
  • Weekends
    11:00PM - 12:00AM
     
    Weekends with Larry Marino features news and information and special guests   >>
     
  • The Best of The Pastor Scott Show
    12:00AM - 2:00AM
     
    The Best Of The Pastor Scott Show - a Compilation of Interviews, Commentary and   >>
     
  • The Larry Elder Show
    2:00AM - 3:00AM
    The Larry Elder Show
    (844) 900-7243
     
    Larry Elder personifies the phrase “We’ve Got a Country to Save” The “Sage from   >>
     

See the Full Program Guide